These data suggested that an inhibitor of the PI3K/AKT/mTOR signaling pathway appears to be a potential therapeutic drug candidate for restoring radiosensitivity in oral cancers that were intrinsically or consequently resistant to RT. Here, MTOR is linked to lip and oral cavity carcinoma.